Solution-focused therapy to improve psychosocial adjustment and medication adherence for people with schizophrenia
The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia
This program will try weekly one-on-one solution-focused therapy for six weeks to see if it helps adults with stable schizophrenia improve social adjustment and stick to their medications.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Muş Alparslan University Academic / other |
| Locations | 1 site (Muş) |
| Trial ID | NCT07144592 on ClinicalTrials.gov |
What this trial studies
This is a randomized controlled trial enrolling 60 clinically stable adults with DSM-5 schizophrenia who are registered at a university-affiliated Community Mental Health Center in Muş, Türkiye. Participants are randomized to receive one individual solution-focused therapy session per week for six weeks plus usual care, or to receive usual care alone. Outcomes include measures of psychosocial adjustment and medication adherence collected before and after the intervention using validated scales. The intervention emphasizes individual strengths, past coping successes, and brief goal-focused strategies delivered by mental health staff.
Who should consider this trial
Good fit: Adults aged 18–65 with a DSM-5 diagnosis of schizophrenia who are clinically stable, literate and verbally communicative, cognitively able to participate, currently on psychiatric treatment and registered at the participating Community Mental Health Center are ideal candidates.
Not a fit: People experiencing acute psychosis, significant cognitive impairment, not registered at the participating center, not currently on medication, or outside the 18–65 age range are unlikely to benefit from this program.
Why it matters
Potential benefit: If effective, the approach could help patients improve daily functioning and medication adherence with a brief, low-intensity therapy that can be delivered in community settings.
How similar studies have performed: Small trials and pilot work using solution-focused or brief strengths-based approaches in mental health have shown promise, but rigorous randomized evidence specifically in schizophrenia is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Having been diagnosed with schizophrenia according to DSM-5 diagnostic criteria, Being between 18 and 65 years of age, Being literate and verbally communicative, Being clinically stable (not exhibiting symptoms of acute psychosis), Being registered with a Community Mental Health Center (CMHC) and receiving regular services, Being cognitively competent enough to participate in individual interviews during the research process, Being an individual currently receiving psychiatric treatment and taking medication, Agreeing to participate voluntarily in the study and signing a written informed consent form. Exclusion Criteria: * those who do not meet the inclusion criteria
Where this trial is running
Muş
- Community Mental Health Center — Muş, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Fatih Şahin, dr
- Email: fatih.sahin@alparslan.edu.tr
- Phone: 0534 688 1634
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.